Table 5 Open in new tab Risks of...

Subgroup analysis

Number of cohorts

Hazard ratio
[95% confidence interval]

I²

p-value

Secondary loss of response [overall]

2.21 [1.69 − 2.88]

<0.001

Patient population

Crohn’s disease patients only

1.79 [0.81 − 3.95]

52%

0.15

Type of TNF-a antagonist

Infliximab exclusively

2.01 [1.36 − 2.97]

44%

<0.001

Adalimumab exclusively

2.46 [1.42 − 4.28]

0.001

Publication type

Abstracts

2.39 [1.69 − 3.37]

<0.001

Full papers

1.94 [1.20 − 3.13]

23%

0.007

Risk of bias

Studies with low/moderate risk of bias

2.00 [1.48 − 2.70]

<0.001

Studies with high risk of bias

3.12 [1.78 − 5.48]

<0.001

Treatment discontinuation [overall]

1.72 [1.10 − 2.70]

68%

0.002

Patient population

Adult patients only

1.84 [1.15 − 2.93]

44%

0.01

Crohn’s disease patients only

2.14 [1.32 − 3.47]

0.002

Type of TNF-a antagonist

Infliximab exclusively

2.11 [1.63 − 2.74]

<0.001

Publication type

Full papers

1.43 [0.74 − 2.77]

79%

0.29

Abstracts

2.39 [1.53 − 3.75]

<0.001

Risk of bias

Excluding high-risk bias studies

1.64 [0.98 − 2.72]

74%

0.06

Table 5

Open in new tab

Risks of secondary loss of clinical response to anti-tumour necrosis factor-alpha drugs and treatment discontinuation in inflammatory bowel disease patients carrying HLA DQA1*05 versus non-carriers. Overall data and subgroup analysis results are provided.

Subgroup analysis	Number of cohorts	Hazard ratio [95% confidence interval]	I²	p-value
Secondary loss of response [overall]	6	2.21 [1.69 − 2.88]	0%	<0.001
Patient population
Crohn’s disease patients only	2	1.79 [0.81 − 3.95]	52%	0.15
Type of TNF-a antagonist
Infliximab exclusively	5	2.01 [1.36 − 2.97]	44%	<0.001
Adalimumab exclusively	2	2.46 [1.42 − 4.28]	0%	0.001
Publication type
Abstracts	4	2.39 [1.69 − 3.37]	0%	<0.001
Full papers	2	1.94 [1.20 − 3.13]	23%	0.007
Risk of bias
Studies with low/moderate risk of bias	4	2.00 [1.48 − 2.70]	0%	<0.001
Studies with high risk of bias	2	3.12 [1.78 − 5.48]	0%	<0.001
Treatment discontinuation [overall]	6	1.72 [1.10 − 2.70]	68%	0.002
Patient population
Adult patients only	2	1.84 [1.15 − 2.93]	44%	0.01
Crohn’s disease patients only	2	2.14 [1.32 − 3.47]	0%	0.002
Type of TNF-a antagonist
Infliximab exclusively	5	2.11 [1.63 − 2.74]	0%	<0.001
Publication type
Full papers	4	1.43 [0.74 − 2.77]	79%	0.29
Abstracts	2	2.39 [1.53 − 3.75]	0%	<0.001
Risk of bias
Excluding high-risk bias studies	5	1.64 [0.98 − 2.72]	74%	0.06

Subgroup analysis	Number of cohorts	Hazard ratio [95% confidence interval]	I²	p-value
Secondary loss of response [overall]	6	2.21 [1.69 − 2.88]	0%	<0.001
Patient population
Crohn’s disease patients only	2	1.79 [0.81 − 3.95]	52%	0.15
Type of TNF-a antagonist
Infliximab exclusively	5	2.01 [1.36 − 2.97]	44%	<0.001
Adalimumab exclusively	2	2.46 [1.42 − 4.28]	0%	0.001
Publication type
Abstracts	4	2.39 [1.69 − 3.37]	0%	<0.001
Full papers	2	1.94 [1.20 − 3.13]	23%	0.007
Risk of bias
Studies with low/moderate risk of bias	4	2.00 [1.48 − 2.70]	0%	<0.001
Studies with high risk of bias	2	3.12 [1.78 − 5.48]	0%	<0.001
Treatment discontinuation [overall]	6	1.72 [1.10 − 2.70]	68%	0.002
Patient population
Adult patients only	2	1.84 [1.15 − 2.93]	44%	0.01
Crohn’s disease patients only	2	2.14 [1.32 − 3.47]	0%	0.002
Type of TNF-a antagonist
Infliximab exclusively	5	2.11 [1.63 − 2.74]	0%	<0.001
Publication type
Full papers	4	1.43 [0.74 − 2.77]	79%	0.29
Abstracts	2	2.39 [1.53 − 3.75]	0%	<0.001
Risk of bias
Excluding high-risk bias studies	5	1.64 [0.98 − 2.72]	74%	0.06

I², statistic inconsistency.

This Feature Is Available To Subscribers Only